INBP logo

Integrated BioPharma, Inc. (INBP) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Integrated BioPharma, Inc. (INBP) opera en el sector Consumer Defensive, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 40/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 40/100

Integrated BioPharma, Inc. (INBP) Descripción General del Negocio al Consumidor

Empleados153
Sede CentralHillside, United States

Integrated BioPharma, Inc. focuses on the manufacturing and distribution of vitamins, nutritional supplements, and herbal products, operating primarily in the United States and Luxembourg. With a presence in both contract manufacturing and direct distribution, the company caters to distributors, multilevel marketers, and specialized healthcare providers within the consumer defensive sector.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Integrated BioPharma, Inc. presents a complex investment case, given its small market capitalization of $0.01 billion and negative profit margin of -0.4%. The company's low gross margin of 7.8% and negative ROE of -1.0% indicate profitability challenges. While the beta of 0.52 suggests lower volatility compared to the market, the high debt-to-equity ratio of 2.55 raises concerns about financial leverage. A key consideration is the company's ability to generate free cash flow, which currently stands at $0.00 billion. Potential investors should carefully evaluate the company's turnaround strategy and its ability to improve profitability and cash flow generation. Upcoming catalysts may include new product launches or expansion into new markets, but these need to be weighed against the potential risks associated with the company's financial performance.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market Cap of $0.01B indicates a micro-cap company with potential for high growth but also higher risk.
  • Negative Profit Margin of -0.4% highlights challenges in achieving profitability.
  • Gross Margin of 7.8% is relatively low compared to industry averages, suggesting potential inefficiencies in production or pricing.
  • Debt-to-Equity Ratio of 2.55 indicates a highly leveraged balance sheet, which could increase financial risk.
  • Beta of 0.52 suggests the stock is less volatile than the overall market.

Competidores y Pares

Fortalezas

  • Established manufacturing capabilities.
  • Existing distribution network.
  • Experience in contract manufacturing.
  • Presence in both US and Luxembourg markets.

Debilidades

  • Low profit margin.
  • High debt-to-equity ratio.
  • Small market capitalization.
  • Limited brand recognition.

Catalizadores

  • Upcoming: Potential new product launches in the vitamin and supplement sector.
  • Upcoming: Expansion into new geographic markets, particularly in Asia.
  • Ongoing: Increasing consumer demand for health and wellness products.
  • Ongoing: Growth in the contract manufacturing market for nutraceuticals.
  • Ongoing: Shift towards e-commerce and direct-to-consumer sales channels.

Riesgos

  • Potential: Intense competition from larger, more established players.
  • Potential: Fluctuations in raw material prices.
  • Potential: Changes in regulations governing the nutraceuticals industry.
  • Ongoing: Low profit margins and high debt levels.
  • Ongoing: Limited liquidity and price volatility due to OTC listing.

Oportunidades de crecimiento

  • Expansion of Contract Manufacturing Services: Integrated BioPharma can capitalize on the growing demand for private label and white label supplements by expanding its contract manufacturing services. The global contract manufacturing market for nutraceuticals is projected to reach $95 billion by 2028. By investing in advanced manufacturing technologies and quality control processes, INBP can attract more clients and increase its production volume, leading to higher revenue and improved profitability. This expansion could be realized within the next 2-3 years.
  • New Product Development and Innovation: Introducing innovative and scientifically-backed nutritional supplements can drive revenue growth. The market for personalized nutrition is expanding rapidly, with consumers seeking customized solutions for their health needs. Integrated BioPharma can invest in research and development to create new products targeting specific health conditions or demographic groups. Successful product launches could significantly boost sales within the next 1-2 years.
  • Geographic Expansion into New Markets: Expanding its distribution network beyond the United States and Luxembourg can unlock new growth opportunities. Emerging markets in Asia and Latin America are experiencing increasing demand for vitamins and supplements. By establishing partnerships with local distributors or setting up its own sales channels, Integrated BioPharma can tap into these high-growth markets. This expansion could take 3-5 years to fully materialize.
  • Strategic Acquisitions and Partnerships: Acquiring complementary businesses or forming strategic partnerships can enhance Integrated BioPharma's capabilities and market reach. For example, acquiring a company with expertise in e-commerce or digital marketing can improve its online sales channels. Partnering with a research institution can accelerate its product development efforts. Such strategic moves could yield significant benefits within the next 2-3 years.
  • Focus on E-commerce and Direct-to-Consumer Sales: The shift towards online shopping presents a significant growth opportunity for Integrated BioPharma. By investing in its e-commerce platform and digital marketing capabilities, the company can reach a wider customer base and increase its direct-to-consumer sales. The online channel offers higher margins and greater control over the customer experience. This strategy can be implemented and generate results within the next 1-2 years.

Oportunidades

  • Expansion of contract manufacturing services.
  • New product development and innovation.
  • Geographic expansion into emerging markets.
  • Increased focus on e-commerce and direct-to-consumer sales.

Amenazas

  • Intense competition in the nutraceuticals market.
  • Changing consumer preferences and regulatory requirements.
  • Fluctuations in raw material prices.
  • Potential product liability claims.

Ventajas competitivas

  • Established manufacturing capabilities.
  • Existing distribution network.
  • Long-standing relationships with suppliers and customers.

Acerca de INBP

Integrated BioPharma, Inc., incorporated in 1980 and based in Hillside, New Jersey, operates within the consumer defensive sector, specifically in packaged foods. The company focuses on the manufacturing, distribution, marketing, and sale of vitamins, nutritional supplements, and herbal products. Its operations are divided into two segments: Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment produces vitamins and nutritional supplements for distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment provides warehousing and fulfillment services, alongside distributing raw materials. Formerly known as Integrated Health Technologies, Inc., the company has established a presence in the United States and Luxembourg. Integrated BioPharma's business model caters to both B2B and potentially B2C channels, leveraging its manufacturing capabilities to supply a range of health and wellness products. The company's history reflects its evolution within the nutraceuticals market, adapting to changing consumer preferences and distribution models.

Qué hacen

  • Manufactures vitamins and nutritional supplements.
  • Distributes vitamins, nutritional supplements, and herbal products.
  • Markets vitamins, nutritional supplements, and herbal products.
  • Offers contract manufacturing services to distributors.
  • Provides warehousing and fulfillment services.
  • Distributes raw materials for supplement production.

Modelo de Negocio

  • Contract manufacturing of vitamins and supplements for other companies.
  • Direct distribution of branded and white-label products.
  • Warehousing and fulfillment services for nutraceutical businesses.

Contexto de la Industria

Integrated BioPharma operates in the packaged foods industry, specifically within the vitamins and supplements segment. This market is characterized by increasing consumer awareness of health and wellness, driving demand for nutritional products. The industry is competitive, with established players and emerging brands vying for market share. Trends include personalized nutrition, clean label products, and e-commerce distribution. Integrated BioPharma's focus on contract manufacturing and distribution positions it within the supply chain, serving both large distributors and specialized healthcare providers. The company's success depends on its ability to maintain quality, innovate with new products, and adapt to changing consumer preferences.

Clientes Clave

  • Distributors of vitamins and supplements.
  • Multilevel marketing companies.
  • Specialized healthcare providers.
  • Consumers (potentially through retail channels).
Confianza de la IA: 71% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Integrated BioPharma, Inc. (INBP): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para INBP.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para INBP.

MoonshotScore

40/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de INBP en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Información del mercado OTC de INBP

The OTCQX tier represents the highest tier of the OTC market, signifying companies that meet certain financial standards, demonstrate compliance with U.S. securities laws, and are current in their disclosure obligations. Unlike companies listed on the NYSE or NASDAQ, OTCQX-listed companies are not subject to the same stringent listing requirements, such as minimum share price and market capitalization thresholds. However, OTCQX provides a platform for established and growing companies to access a wider investor base while benefiting from streamlined regulatory processes compared to lower OTC tiers.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Trading volume for OTCQX stocks like Integrated BioPharma can be significantly lower than that of NYSE or NASDAQ-listed companies. Bid-ask spreads may also be wider, reflecting the lower liquidity and potential price volatility. This can make it more challenging to buy or sell large quantities of shares without impacting the market price. Investors should exercise caution and consider using limit orders to manage their trading execution.
Factores de riesgo OTC:
  • Limited liquidity compared to major exchanges.
  • Wider bid-ask spreads, potentially increasing transaction costs.
  • Less stringent regulatory oversight than NYSE or NASDAQ.
  • Potential for greater price volatility.
  • Information asymmetry due to less analyst coverage.
Lista de verificación de diligencia debida:
  • Verify the company's financial statements and SEC filings.
  • Assess the company's management team and corporate governance practices.
  • Analyze the company's competitive landscape and market position.
  • Evaluate the company's growth prospects and potential catalysts.
  • Review the company's risk factors and potential liabilities.
  • Check for any legal or regulatory issues.
  • Monitor trading volume and price volatility.
Señales de legitimidad:
  • OTCQX tier listing indicates a higher level of compliance and disclosure.
  • Current disclosure status suggests a commitment to transparency.
  • Long operating history since incorporation in 1980.
  • Audited financial statements (verify availability).
  • Positive news coverage or industry recognition (if any).

Acciones de Integrated BioPharma, Inc.: Preguntas Clave Respondidas

¿Cuáles son los factores clave para evaluar INBP?

Integrated BioPharma, Inc. (INBP) actualmente tiene una puntuación IA de 40/100, indicando puntuación baja. Fortaleza clave: Established manufacturing capabilities.. Riesgo principal a monitorear: Potential: Intense competition from larger, more established players.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de INBP?

INBP actualmente puntúa 40/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de INBP?

Los precios de INBP se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre INBP?

La cobertura de analistas para INBP incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en INBP?

Las categorías de riesgo para INBP incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from larger, more established players.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de INBP?

La relación P/E para INBP compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está INBP sobrevalorada o infravalorada?

Determinar si Integrated BioPharma, Inc. (INBP) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de INBP?

Integrated BioPharma, Inc. (INBP) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited analyst coverage may affect the availability of information.
  • OTC market stocks carry higher risk than exchange-listed stocks.
Fuentes de datos

Popular Stocks